1stOncology™: Cancer Intelligence Service – Page 620 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

On August 20, 2025 PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company"), reported the closing of its previously announced $7 million financing (Press release, PharmaCyte Biotech, AUG 20, 2025, View Source [SID1234655409]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company’s most recent 10K. With the addition of the $7 million in proceeds from this financing, the Company’s balance sheet has been further strengthened, providing significant financial flexibility to support its ongoing business initiatives and strategic growth opportunities.

"The successful completion of this financing is a welcome milestone as we continue on our growth trajectory," said Josh Silverman, Interim Chief Executive Officer of PharmaCyte. "We expect this additional capital, combined with our substantially reduced operational burn rate and our existing cash position and investments, to bring substantial value to our shareholders as we advance our initiatives and continue to evaluate opportunities that align with our long-term strategy."

As of the date of this release, PharmaCyte has approximately 6.8 million shares of common stock outstanding.

Gilead Sciences to Present at Upcoming Investor Conferences

On August 20, 2025 Gilead Sciences, Inc. (Nasdaq: GILD) reported that its executives will be speaking at the following investor conferences (Press release, Gilead Sciences, AUG 20, 2025, View Source [SID1234655408]):

Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM Eastern Time
Wells Fargo Healthcare Conference on Thursday, September 4 at 11:00 AM Eastern Time
Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 9 at 10:45 AM Eastern Time
Baird Global Healthcare Conference on Wednesday, September 10 at 11:25 AM Eastern Time

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

On August 20, 2025 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City (Press release, TuHURA Biosciences, AUG 20, 2025, https://tuhurabio.com/tuhura-biosciences-inc-to-present-at-the-27th-annual-h-c-wainwright-global-investment-conference/ [SID1234655407]).

James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows:

27th Annual H.C. Wainwright Global Investment Conference

Date:

Monday, September 8, 2025

Time:

2:30 PM Eastern Time

Link:

Click Here

A replay of the presentation will be available on the Events page of the Investors section of the Company’s website (tuhurabio.com). For more information about the event, please visit the conference website.

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

On August 20, 2025 Sana Biotechnology, Inc. (Nasdaq: SANA) ("Sana"), a company focused on changing the possible for patients through engineered cells, reported that it has closed the sale of 3,358,208 shares of its common stock at a price to the public of $3.35 per share, pursuant to the exercise in full of the underwriters’ option to purchase additional shares in connection with Sana’s previously announced underwritten public offering, which closed on August 8, 2025 (Press release, Sana Biotechnology, AUG 20, 2025, View Source [SID1234655406]). All of the shares were sold by Sana. Total gross proceeds from the offering, including the full exercise of the underwriters’ option, were approximately $86.3 million, before deducting underwriting discounts and commissions and other offering expenses.

Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen acted as joint book-running managers for the offering.

The offering was made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC. Sana has filed with the SEC the final prospectus supplement and accompanying prospectus relating to the offering. These documents can be accessed for free through the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at [email protected]; Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected]; BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at [email protected]; or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

Olema Oncology to Participate in Upcoming Investor Conferences

On August 20, 2025 Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that the Company will participate in the following upcoming investor conferences (Press release, Olema Oncology, AUG 20, 2025, View Source [SID1234655405]):

Citi’s 2025 Biopharma Back to School Conference
Date and Time: September 2, 2025 at 4 p.m. ET
Format: Fireside Chat
Location: Boston, MA

Wells Fargo 2025 Healthcare Conference
Date and Time: September 3, 2025 at 3:45 p.m. ET
Format: Presentation
Location: Boston, MA

Cantor Global Healthcare Conference 2025
Date and Time: September 4, 2025 at 11:30 a.m. ET
Format: Fireside Chat
Location: New York, NY

Morgan Stanley 23rd Annual Global Healthcare Conference
Date and Time: September 8, 2025 at 10 a.m. ET
Format: Fireside Chat
Location: New York, NY

H.C. Wainwright 27th Annual Global Investment Conference
Date and Time: September 9, 2025 at 9:30 a.m. ET
Format: Fireside Chat
Location: New York, NY

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.